Liver Function and Inhaled Anesthetics
Article information
J Korean Med Assoc. 2006;49(12):1126-1138
Publication date (electronic) : 2006 December 31
doi :
https://doi.org/10.5124/jkma.2006.49.12.1126
Abstract
The liver is the major site of endogenous and exogenous drug metabolism. The primary result of drug metabolism is the production of more water-soluble and therefore more easily excreted drug metabolites. Drugs are sometimes biotransformed into more reactive metabolites, which may lead to toxicity. Volatile anesthetics, like most drugs, undergo metabolism in the body and are sometimes associated with toxic reactions. Here, author will discuss the metabolism and hepatic toxicity of inhaled anesthetics. Toxicity and liver injury have been reported after repeated exposure on subsequent occasions to different fluorinated anesthetics. This phenomenon of cross-sensitization has also been reported with the chlorofluorocarbon(CFC) replacement agents, the hydrochlorofluorocarbons(HCFCs). Halothane, enflurane, sevoflurane, isoflurane, desflurane are all metabolized to trifluoroacetic acid, which have been reported to induce liver injury in susceptible patients. The propensity to produce liver injury appears to parrel metabolism of the parent drug: halothane(20%) >>>> enflurane(2.5%) >> sevoflurane(1%) > isoflurane(0.2%) > desflurane(0.02%). The use of any anesthetic must be based on its benefits and risks, how it may produce toxicity, and in which patients it may be most safely administered. Nonhalogenated inhaled anesthetics (nitrous oxide, xenon) chemically inert and not metabolized in human tissue. The perfect anesthetic agents dose not exist. But ongoing research attempts to uncover emerging toxicities. Xenon is not currently approved for clinical use. Other than the expense associated with its use, it may be the most ideal anesthetic agent. In general, surgical manipulation or disturbance of the surgical site appears to be more important in decreasing hepatic blood flow than current anesthetic agents such as isoflurane, sevoflurane, and desflurane or technique. However, the clinician is challenged to balance new information with current clinical practices and choice the safest, most effective agents for each patient.
References
1. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinet 1994. 26144–160.
2. Wilkinson G. In : Hardmann JG, Limbrid LE, Goodman GA, eds. Pharmacokinetics. The dynamics of drug absorption, distribution and elimination. Goodman and Gilman's the Pharmacological Basis of Therapeutics 2001. 10th edth ed. New York: McGraw-Hill;
3. Gibson GG, Skett P. Introduction to drug metabolism 1999. Chelteham, UK: Stanley, Thornes Publishers;
4. Banks RGS, Henderson RJ, Pratt JM. Reactions of gases in solution. Some reactions of nitrous with transition metal complexes. J Chem Soc 1968. 3Suppl A. 2886.
5. Amess JA, Burman JF, Ree GM, Nancekievill DG, Mollin DL. Megaloblastic haemopoiesis in patients receiving nitrous oxide. Lancet 1978. 12339–342.
6. Van Dyke RA. In : Chenoweth MB, ed. Biotransformation. Handbook of Experimental pharmacology 1972. New York: Springer-Verlag; 354.
7. Rao GS, Meridian DJ, Tong YS. Biochemical toxicology of chronic nitrous oxide exposures. Pharmacologist 1979. 21216.
8. Rice SA, Mazze RI, Baden JM. Effects of subchronic intermittent exposure to nitrous oxide in Swiss Webster mice. J Environ Pathol Toxicol Oncol 1985. 6271–281.
9. Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951. 113580–582.
10. Morris LE, Knott JR, Pittinger CB. Electroencephalographic and blood gas observations in human surgical patients during xenon anesthesia. Anesthesiology 1955. 16312–319.
11. Lachmann B, Armbruster S, Schairer W, Landstra M, Trouwborst A, Van Daal GJ, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990. 3351413–1415.
12. Luttropp HH, Thomasson R, Dahm S, Persson J, Werner O. Clinical experience with minimal flow xenon anesthesia. Acta Anaesthesiol Scand 1994. 38121–125.
13. Hofland J, Gultuna I, Tenbrinck R. Xenon anaesthesia for laparoscopic cholecystectomy in a patient with Eisenmenger's syndrome. Br J Anaesth 2001. 86882–886.
14. Burov NE, Molchanov IV, Nikolaev LL, Rashchupkin AB. [The method of low-flow xenon anesthesia]. Anesteziol Reanimatol 2003. 331–34.
15. Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Anesthesiology 1997. 861273–1278.
16. Rossaint R, Reyle-Hahn M, Schulte AM Esch J, Scholz J, Scherpereel P, Vallet B, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology 2003. 986–13.
17. Froeba G, Marx T, Pazhur J, Baur C, Baeder S, Calzia E, et al. Xenon does not trigger malignant hyperthermia in susceptible swine. Anesthesiology 1999. 911047–1052.
18. Zhang P, Ohara A, Mashimo T, Imanaka H, Uchiyama A, Yoshiya I. Pulmonary resistance in dogs: A comparison of xenon with nitrous oxide. Can J Anaesth 1995. 42547–553.
19. Kharasch ED, Hankins DC, Fenstamaker K, Cox K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur J Clin Pharmacol 2000. 55853–859.
20. Brody GL, Sweet RB. Halothane anesthesia as a possible cause of massive hepatic necrosis. Anesthesiology 1963. 2429–37.
21. Subcommittee on the National Halothane Study of the Committee on Anesthesia. National Academy of Sciences: National Research Council. Summary of the National Halothane Study. Possible association between halothane anesthesia and postoperative necrosis. JAMA 1966. 197775–788.
22. Lewis RB, Blair M. Halothane hepatitis in a young child. Br J Anaesth 1982. 54349–354.
23. Pohl LR. An immunochemical approach of identifying and characterizing protein targets of toxic reactive metabolites. Chem Res Toxicol 1993. 6786–793.
24. Joshi PH, Conn HO. The syndrome of methoxyflurane associated hepatitis. Ann Intern Med 1974. 80395–401.
25. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity: A study of dose response in man. JAMA 1973. 2251611–1616.
26. Eger EI II, Smuckler EA, Ferrell LD, Goldsmith CH, Johnson BH. Is enflurane hepatotoxic? Anesth Analg 1986. 6521–30.
27. Sigurdsson J, Hreidarsson AB, Thjodleifsson B. Enflurane hepatitis: A report of a case with a previous history of halothane hepatitis. Acta Anaesthesiol Scand 1985. 29495–496.
28. Christ DD, Kenna JG, Kammerer W, Satoh H, Pohl LR. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988. 69833–838.
29. Stoelting RK, Blitt CD, Cohen PJ, Merin RG. Hepatic dysfunction after isoflurane anesthesia. Anesth Analg 1987. 66147–153.
30. Brunt EM, White H, Marsh JW, Holtmann B, Peters MG. Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: A case report. Hepatology 1991. 131017–1021.
31. Turner GB, O'Rourke D, Scott GO, Beringer TR. Fatal hepatotoxicity after re-exposure to isoflurane: A case report and review of the literature. Eur J Gastroenterol Hepatol 2000. 12955–959.
32. Njoku DB, Shrestha S, Soloway R, Duray PR, Tsokos M, Abu-Asab MS, et al. Subcellular localization of trifluoroacetylated liver proteins in association with hepatitis following isoflurane. Anesthesiology 2002. 96757–761.
33. Jones RM, Koblin DD, Cashman JN, Eger EI II, Johnson BH, Damask MC. Biotransformation and hepato-renal function in volunteers after exposure to desflurane (I-653). Br J Anaesth 1990. 68482–487.
34. Wrigley SR, Fairfield JE, Jones RM, Black AE. Induction and recovery characteristics of desflurane in day case patients: A comparison with propofol. Anaesthesia 1991. 46615–622.
35. Eger EI II, Johnson BH, Strum DP, Ferrell LD. Studies of the toxicity of I-653, halothane, and isoflurane in enzyme induced, hypoxic rat. Anesth Analg 1987. 661227–1229.
36. Martin JL, Plevak DJ, Flannery KD, Charlton M, Poterucha JJ, Humphreys CE, et al. Hepatotoxicity after desflurane anesthesia. Anesthesiology 1995. 831125–1129.
37. Berghaus TM, Baron A, Geier A, Lamerz R, Paumgartner G. Hepatotoxicity following desflurane anesthesia. Hepatology 1999. 29613–614.
38. Gonsowiski CT, Laster MJ, Eger EI II, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats. Anesthesiology 1994. 80556–565.
39. Keller KA, Callan C, Prokocimer P, Delgado-Herrera L, Friedman MB, Hoffman GM, et al. Inhalation toxicity study of a haloalkene degradant of sevoflurane, compound A (PIFE), in Sprague-Dawley rats. Anesthesiology 1995. 831220–1232.
40. Goldberg ME, Cantillo J, Gratz I, Deal E, Vekeman D, McDougall R, et al. Dose of compound A, not sevoflurane, determines changes in the biochemical markers of renal injury in healthy volunteers. Anesth Analg 1999. 88437–445.
41. Ebert TJ, Messana LD, Uhrich TD, Staacke TS. Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers. Anesth Analg 1998. 86662–667.
42. Watanabe K, Hatakenaka S, Ikemune K, Chigyo Y, Kubozone T, Arai T. A case of suspected liver dysfunction induced by sevoflurane anesthesia. Masui 1993. 42902–905.
43. Shichinohe Y, Masuda Y, Takahashi H, Kotaki M, Omoto T, Shichinohe M, et al. A case of postoperative hepatic injury after sevoflurane anesthesia. Masui 1992. 411802–1805.
44. Bruun LS, Elkjaer S, Bitsch-Larsen D, Andersen O. Hepatic failure in a child after acetaminophen and sevoflurane exposure. Anesth Analg 2001. 921446–1448.
45. Frink EJ Jr, Ghantous H, Malan TP, Morgan S, Fernando J, Gandolfi AJ, et al. Plasma inorganic fluoride with sevoflurane anesthesia: Correlation with indices of hepatic and renal function. Anesth Analg 1992. 74231–235.
46. Ray DC, Bomont R, Mizushima A, Kugimiya T, Forbes Howie A, Beckett GJ. Effect of sevoflurane anesthesia on plasma concentrations of glutathione S-transferase. Br J Anaesth 1996. 77404–407.
47. Taivainen T, Tiainen P, Meretoja OA, Raiha L, Rosenberg PH. Comparison of the effects of sevoflurane and halothane on the quality of anaesthesia and serum glutathione transferase alpha and fluoride in paediatric patients. Br J Anaesth 1994. 73590–595.
48. Lynch S, Martis L, Woods E. Evaluation of hepatotoxic potential of sevoflurane in rats. Pharmacologist 1979. 21221.
49. Molina DM, Rowland FS. Stratospheric sink for chlorofluoromethanes: Chlorine atom-catalyzed destruction of ozone. Nature 1974. 249810–812.
50. Hoet P, Graf ML, Bourdi M, Pohl LR, Duray PH, Chen W, et al. Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 1997. 350556–559.
Article information Continued
Copyright © 2006 Korean Medical Association
